Aspirin/paracetamol/caffeine
| Combination of | |
|---|---|
| Aspirin | NSAID |
| Paracetamol | Analgesic |
| Caffeine | Stimulant |
| Clinical data | |
| Trade names | Excedrin |
| AHFS/Drugs.com | entry |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| ATC code | N02BA51 |
Aspirin/paracetamol/caffeine is a combination drug for the treatment of pain, especially tension headache and migraine.[1] It is sold in the US under the trade name Excedrin, although not all products sold under this name contain this combination.
Adverse effects
The recommended dosing has a low risk profile when taken occasionally in a well hydrated state. As with all medications containing paracetamol (acetaminophen), concomitant use with alcohol carries a significant risk of hepatotoxicity. The combination of paracetamol with aspirin also creates the risk of renal papillary necrosis if large doses are taken chronically. This is because paracetamol yields a toxic metabolite that can accumulate in the kidney while aspirin works to deplete the glutathione stores necessary to oxidize it. Additionally, chronic aspirin usage is associated with increased risk of gastrointestinal bleeding.[2]
Chemical detection
The combination of these three compounds can be detected in pharmaceutical formulations, urine and blood serum in trace quantities using electrochemical methods.[3]
Other trade names
In Germany, this combination is sold as Chephapyrin, dolomo, Dolopyrin, HA-Tabletten N, Melabon, Neuralgin, Novo Petrin, ratiopyrin, Thomapyrin CLASSIC, Thomapyrin INTENSIV, TITRALGAN, in Austria as Thomapyrin, InfluASS, Irocophan, in Israel as Acamol Focus and in Russia as Citramon.
References
- ↑ Drugs.com: entry
- ↑ Henrich, W; Lawrence E. Agodoa; Brendan Barrett; William M. Bennett; Roland C. Blantz; Vardaman M. Buckalew Jr; Vivette D. D'Agati; Marc E. DeBroe; Geoffrey G. Duggin; Garabed Eknoyan; Monique M. Elseviers; R.Ariel Gomez; Gary R. Matzke; George A. Porter; Sandra Sabatin; Jeffrey S. Stoff; Gary E. Striker; James F. Winchester (1996). "Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committee of the National Kidney Foundation". American Journal of Kidney Diseases 27: 162–165. doi:10.1016/S0272-6386(96)90046-3.
- ↑ Sanghavi, BJ; Srivastava, AK (2010). "Simultaneous voltammetric determination of acetaminophen, aspirin andcaffeine using an in situ surfactant-modified multiwalled carbonnanotube paste electrode". Electrochimica Acta 55 (28): 8638–48. doi:10.1016/j.electacta.2010.07.093.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||